PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 22, Issue 7, Pages 3464
Publisher
MDPI AG
Online
2021-03-29
DOI
10.3390/ijms22073464
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phosphoinositide 3-Kinase (PI3K) Reactive Oxygen Species (ROS)-Activated Prodrug in Combination with Anthracycline Impairs PI3K Signaling, Increases DNA Damage Response and Reduces Breast Cancer Cell Growth
- (2021) Rosalin Mishra et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Phase 1 cohort expansion study of LY3023414, a dual PI3K/mTOR inhibitor, in patients with advanced mesothelioma
- (2021) Marjorie G. Zauderer et al. INVESTIGATIONAL NEW DRUGS
- Open Label Non-Randomized Phase II Study Exploring «Chemo-Free » Treatment Association with Idelalisib + Obinutuzumab in Patients with Relapsed/Refractory (R/R) Waldenstrom's Macroglobulinemia (MW), a Filo Trial: Results of the Intermediary Analysis of the Induction Phase
- (2020) Cecile Tomowiak et al. BLOOD
- A Phase I study of safety, pharmacokinetics, and pharmacodynamics of concurrent everolimus and buparlisib treatment in advanced solid tumors
- (2020) Taofeek K. Owonikoko et al. CLINICAL CANCER RESEARCH
- Role of non-coding RNAs and RNA modifiers in cancer therapy resistance
- (2020) Xinyi Zhang et al. Molecular Cancer
- Structural variation and its potential impact on genome instability: Novel discoveries in the EGFR landscape by long-read sequencing
- (2020) George W. Cook et al. PLoS One
- Imatinib in combination with phosphoinositol kinase inhibitor buparlisib in patients with gastrointestinal stromal tumour who failed prior therapy with imatinib and sunitinib: a Phase 1b, multicentre study
- (2020) Hans Gelderblom et al. BRITISH JOURNAL OF CANCER
- Phase Ib Study of Tirabrutinib in Combination with Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia
- (2020) Alexey V. Danilov et al. CLINICAL CANCER RESEARCH
- A phase II, multicenter study of encorafenib/binimetinib followed by a rational triple-combination after progression in patients with advanced BRAF V600-mutated melanoma (LOGIC2).
- (2020) Reinhard Dummer et al. JOURNAL OF CLINICAL ONCOLOGY
- Acalabrutinib (Acala) versus idelalisib plus rituximab (IdR) or bendamustine plus rituximab (BR) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): ASCEND final results.
- (2020) Paolo Ghia et al. JOURNAL OF CLINICAL ONCOLOGY
- IND.216: a phase II study of buparlisib and associated biomarkers, raptor and p70S6K, in patients with relapsed and refractory chronic lymphocytic leukemia
- (2020) Sarit Assouline et al. LEUKEMIA & LYMPHOMA
- Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer
- (2020) Ramesh K. Ramanathan et al. Targeted Oncology
- Development of a bioavailable boron-containing PI-103 Bioisostere, PI-103BE
- (2020) Lan Luo et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Phase 1 dose-escalation study of a novel oral PI3K/mTOR dual inhibitor, LY3023414, in patients with cancer
- (2020) Shunsuke Kondo et al. INVESTIGATIONAL NEW DRUGS
- PTEN Alterations and Their Role in Cancer Management: Are We Making Headway on Precision Medicine?
- (2020) Nicola Fusco et al. Genes
- Buparlisib plus carboplatin or lomustine in patients with recurrent glioblastoma: a phase Ib/II, open-label, multicentre, randomised study
- (2020) Mark Rosenthal et al. ESMO Open
- Phase I, open-label, multicentre study of buparlisib in combination with temozolomide or with concomitant radiation therapy and temozolomide in patients with newly diagnosed glioblastoma
- (2020) Patrick Yung Wen et al. ESMO Open
- 568P Phase I dose-escalation study of the dual PI3K/mTORC1/2 inhibitor Gedatolisib (PF-05212384) in combination with paclitaxel (P) and carboplatin (C) in patients (pts) with advanced solid tumours
- (2020) I. Colombo et al. ANNALS OF ONCOLOGY
- Overexpression of ABCB1 and ABCG2 contributes to reduced efficacy of the PI3K/mTOR inhibitor samotolisib (LY3023414) in cancer cell lines
- (2020) Chung-Pu Wu et al. BIOCHEMICAL PHARMACOLOGY
- Phase I/Ib Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma
- (2020) Auris Huen et al. Cancers
- B591, a novel specific pan-PI3K inhibitor, preferentially targets cancer stem cells
- (2019) Hongyu Zhou et al. ONCOGENE
- Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial
- (2019) Loretta J Nastoupil et al. Lancet Haematology
- Challenges for the Clinical Development of PI3K Inhibitors: Strategies to Improve Their Impact in Solid Tumors
- (2019) Ariella B. Hanker et al. Cancer Discovery
- A dual pathway inhibition strategy using BKM120 combined with vemurafenib is poorly tolerated in BRAF V600E/K mutant advanced melanoma
- (2019) Alain Patrick Algazi et al. Pigment Cell & Melanoma Research
- Targeting PI3K in cancer: mechanisms and advances in clinical trials
- (2019) Jing Yang et al. Molecular Cancer
- Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial
- (2019) Panagiotis A Konstantinopoulos et al. LANCET ONCOLOGY
- DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma
- (2019) Ian W. Flinn et al. JOURNAL OF CLINICAL ONCOLOGY
- Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial
- (2019) Patrick Y. Wen et al. JOURNAL OF CLINICAL ONCOLOGY
- A PHASE II STUDY OF PX-866 IN PATIENTS WITH RECURRENT OR METASTATIC CASTRATION RESISTANT PROSTATE CANCER: CANADIAN CANCER TRIALS GROUP STUDY IND205
- (2019) Sebastien J. Hotte et al. Clinical Genitourinary Cancer
- A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB)
- (2019) Ingrid A. Mayer et al. CLINICAL CANCER RESEARCH
- Insulin-Driven PI3K-AKT Signaling in the Hepatocyte Is Mediated by Redundant PI3Kα and PI3Kβ Activities and Is Promoted by RAS
- (2019) Angela Molinaro et al. Cell Metabolism
- PIPA: A phase Ib study of selective ß-isoform sparing phosphatidylinositol 3-kinase (PI3K) inhibitor taselisib (T) plus palbociclib (P) in patients (pts) with advanced solid cancers—Safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) analysis of the doublet combination.
- (2019) Juanita Suzanne Lopez et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 1b/2 study of enzalutamide (ENZ) with LY3023414 (LY) or placebo (PL) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) after progression on abiraterone.
- (2019) Christopher Sweeney et al. JOURNAL OF CLINICAL ONCOLOGY
- Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer
- (2019) Fabrice André et al. NEW ENGLAND JOURNAL OF MEDICINE
- A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancer
- (2019) Vandana G. Abramson et al. BREAST CANCER RESEARCH AND TREATMENT
- Alpelisib: First Global Approval
- (2019) Anthony Markham DRUGS
- Brief Report: SWOG S1400B (NCT02785913), A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
- (2019) Corey J. Langer et al. Journal of Thoracic Oncology
- Author Correction: Macrophages confer resistance to PI3K inhibitor GDC-0941 in breast cancer through the activation of NF-κB signaling
- (2019) Muhammad Waqas Usman et al. Cell Death & Disease
- A phase Ib study of a PI3Kinase inhibitor BKM120 in combination with panitumumab in patients with KRAS wild-type advanced colorectal cancer
- (2019) Rachel Goodwin et al. INVESTIGATIONAL NEW DRUGS
- Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
- (2019) Cristina Saura et al. LANCET ONCOLOGY
- Phase Ib Study of Combination Therapy with MEK Inhibitor Binimetinib and Phosphatidylinositol 3‐Kinase Inhibitor Buparlisib in Patients with Advanced Solid Tumors with RAS/RAF Alterations
- (2019) Aditya Bardia et al. ONCOLOGIST
- Combination trial of duvelisib (IPI‐145) with rituximab or bendamustine/rituximab in patients with non‐Hodgkin lymphoma or chronic lymphocytic leukemia
- (2019) Ian W. Flinn et al. AMERICAN JOURNAL OF HEMATOLOGY
- A Multicentre, Retrospective Observational Study to Evaluate the Clinical Outcomes of Patients with Chronic Lymphocytic Leukaemia (CLL) Treated with Idelalisib and Rituximab in the UK (RETRO-idel) - a Cohort of 110 Patients
- (2019) Toby A. Eyre et al. BLOOD
- Oxidative Cyclization‐Induced Activation of a Phosphoinositide 3‐Kinase Inhibitor for Enhanced Selectivity of Cancer Chemotherapeutics
- (2019) Haizhou Zhu et al. ChemMedChem
- 11C-Labeled Pictilisib (GDC-0941) as a Molecular Tracer Targeting Phosphatidylinositol 3-Kinase (PI3K) for Breast Cancer Imaging
- (2019) Na Han et al. Contrast Media & Molecular Imaging
- On-Target Pharmacodynamic Activity of the PI3K Inhibitor Copanlisib in Paired Biopsies from Patients with Malignant Lymphoma and Advanced Solid Tumors
- (2019) Franck Morschhauser et al. MOLECULAR CANCER THERAPEUTICS
- TBCRC 032 IB/II Multicenter Study: Molecular insights to AR antagonist and PI3K inhibitor efficacy in patients with AR+ metastatic triple-negative breast cancer
- (2019) Brian D. Lehmann et al. CLINICAL CANCER RESEARCH
- Phosphatidylinositol 3 kinase (PI3K) inhibitors as new weapon to combat cancer
- (2019) Fatma M. Elmenier et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- lncRNA CCAT1 promotes cell proliferation, migration, and invasion by down-regulation of miR-143 in FTC-133 thyroid carcinoma cell line
- (2018) Tianzheng Yang et al. BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH
- Phase I dose-escalation study of copanlisib in combination with gemcitabine or cisplatin plus gemcitabine in patients with advanced cancer
- (2018) R D Kim et al. BRITISH JOURNAL OF CANCER
- Metabolic Determinants of Sensitivity to Phosphatidylinositol 3-Kinase Pathway Inhibitor in Small-Cell Lung Carcinoma
- (2018) Hideki Makinoshima et al. CANCER RESEARCH
- First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13)
- (2018) Andreas Wicki et al. EUROPEAN JOURNAL OF CANCER
- Knockdown of long non-coding RNA HOTAIR inhibits cisplatin resistance of gastric cancer cells through inhibiting the PI3K/Akt and Wnt/β-catenin signaling pathways by up-regulating miR-34a
- (2018) Chuanyao Cheng et al. INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
- Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study
- (2018) Dejan Juric et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER.
- (2018) Jose Baselga et al. JOURNAL OF CLINICAL ONCOLOGY
- Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study
- (2018) Howard A Burris et al. LANCET ONCOLOGY
- Linc00659, a long noncoding RNA, acts as novel oncogene in regulating cancer cell growth in colorectal cancer
- (2018) Kuo-Wang Tsai et al. Molecular Cancer
- PTEN/PTENP1: ‘Regulating the regulator of RTK-dependent PI3K/Akt signalling’, new targets for cancer therapy
- (2018) Nahal Haddadi et al. Molecular Cancer
- The long non-coding RNA PTTG3P promotes cell growth and metastasis via up-regulating PTTG1 and activating PI3K/AKT signaling in hepatocellular carcinoma
- (2018) Jin-lan Huang et al. Molecular Cancer
- KDM6B counteracts EZH2-mediated suppression of IGFBP5 to confer resistance to PI3K/AKT inhibitor treatment in breast cancer
- (2018) Wenyu Wang et al. MOLECULAR CANCER THERAPEUTICS
- Downregulation of lncRNA H19 inhibits the migration and invasion of melanoma cells by inactivating the NF‑κB and PI3K/Akt signaling pathways
- (2018) Zhichao Liao et al. Molecular Medicine Reports
- Targeting the PI3K pathway in cancer: are we making headway?
- (2018) Filip Janku et al. Nature Reviews Clinical Oncology
- Genetic disorders: PI3K inhibitor reverses overgrowth syndrome
- (2018) Sarah Crunkhorn NATURE REVIEWS DRUG DISCOVERY
- Long noncoding RNA ATB promotes proliferation, migration and invasion in bladder cancer by suppressing microRNA-126
- (2018) Xingquan Zhai et al. ONCOLOGY RESEARCH
- Skp2-dependent reactivation of AKT drives resistance to PI3K inhibitors
- (2018) Emilie Clement et al. Science Signaling
- Long noncoding RNA RP4 functions as a competing endogenous RNA through miR-7-5p sponge activity in colorectal cancer
- (2018) Mu-Lin Liu et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Prostate Power Play: Does Pik3ca Accelerate Pten -Deficient Cancer Progression?
- (2018) Joanna Triscott et al. Cancer Discovery
- Long Noncoding RNA LINC003121 Inhibits Proliferation and Invasion of Thyroid Cancer Cells by Suppression of the Phosphatidylinositol-3-Kinase (PI3K)/Akt Signaling Pathway
- (2018) Xiang Min et al. MEDICAL SCIENCE MONITOR
- Skp2-dependent reactivation of AKT drives resistance to PI3K inhibitors
- (2018) Emilie Clement et al. Science Signaling
- Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial
- (2018) Jennifer R Brown et al. Lancet Haematology
- Clinical and biomarker results from phase I/II study of PI3K inhibitor BYL 719 (alpelisib) plus nab-paclitaxel in HER2-negative metastatic breast cancer.
- (2018) Priyanka Sharma et al. JOURNAL OF CLINICAL ONCOLOGY
- Effects of rifampin on the pharmacokinetics of copanlisib, a novel pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor in cancer patients.
- (2018) Anna Spreafico et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase I study of the PI3K inhibitor buplarlisib (B) with concurrent chemoradiotherapy (CRT) in patients with high risk locally advanced squamous cell cancer of the head and neck (LASCCHN).
- (2018) Jochen H. Lorch et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase 2 study to assess the safety and efficacy of umbralisib (TGR-1202) in pts with CLL who are intolerant to prior BTK or PI3Kδ inhibitor therapy.
- (2018) Anthony R. Mato et al. JOURNAL OF CLINICAL ONCOLOGY
- Mechanisms behind resistance to PI3K Inhibitor treatment induced by the PIM kinase
- (2018) Jin H. Song et al. MOLECULAR CANCER THERAPEUTICS
- Suppression of insulin feedback enhances the efficacy of PI3K inhibitors
- (2018) Benjamin D. Hopkins et al. NATURE
- ERK-TSC2 signalling in constitutively-active HRAS mutant HNSCC cells promotes resistance to PI3K inhibition
- (2018) Kara M. Ruicci et al. ORAL ONCOLOGY
- Co-activation of super-enhancer-driven CCAT1 by TP63 and SOX2 promotes squamous cancer progression
- (2018) Yuan Jiang et al. Nature Communications
- A Phase Ib, open-label, dose-finding study of alpelisib in combination with paclitaxel in patients with advanced solid tumors
- (2018) Jordi Rodon et al. Oncotarget
- The Network of Non-coding RNAs in Cancer Drug Resistance
- (2018) Fabio Corrà et al. Frontiers in Oncology
- 833PAZD8186, a potent and selective inhibitor of PI3Kβ/δ, as monotherapy and in combination with abiraterone acetate plus prednisone (AAP), in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC)
- (2018) J S de Bono et al. ANNALS OF ONCOLOGY
- LBA3_PRAlpelisib (ALP) + fulvestrant (FUL) for advanced breast cancer (ABC): Results of the phase III SOLAR-1 trial
- (2018) F André et al. ANNALS OF ONCOLOGY
- The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL
- (2018) Ian W. Flinn et al. BLOOD
- A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid tumours
- (2018) Alison M. Schram et al. BRITISH JOURNAL OF CANCER
- A phase I study of single-agent BEZ235 special delivery system sachet in Japanese patients with advanced solid tumors
- (2018) Masanori Toyoda et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A Phase 1 Study of Alpelisib (BYL719), an α- Specific PI3K Inhibitor, in Japanese Patients with Advanced Solid Tumors
- (2018) Yuichi Ando et al. CANCER SCIENCE
- Duvelisib: First Global Approval
- (2018) Hannah A. Blair DRUGS
- Long noncoding RNA OIP5‐AS1 causes cisplatin resistance in osteosarcoma through inducing the LPAATβ/PI3K/AKT/mTOR signaling pathway by sponging the miR‐340‐5p
- (2018) Lei Song et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- The PIK3CA E542K and E545K mutations promote glycolysis and proliferation via induction of the β-catenin/SIRT3 signaling pathway in cervical cancer
- (2018) Wei Jiang et al. Journal of Hematology & Oncology
- Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1–1b study
- (2018) Matthew S Davids et al. Lancet Haematology
- Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor–Positive Advanced Breast Cancer
- (2018) Dejan Juric et al. JAMA Oncology
- Immuno-oncology agent IPI-549 is a modulator of P-glycoprotein (P-gp, MDR1, ABCB1)-mediated multidrug resistance (MDR) in cancer: In vitro and in vivo
- (2018) Albert A. De Vera et al. CANCER LETTERS
- Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer
- (2017) Christophe Massard et al. EUROPEAN JOURNAL OF CANCER
- Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE)
- (2017) Sibylle Loibl et al. EUROPEAN JOURNAL OF CANCER
- Long noncoding RNA HULC promotes cell proliferation by regulating PI3K/AKT signaling pathway in chronic myeloid leukemia
- (2017) Yinghao Lu et al. GENE
- Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma
- (2017) Anas Younes et al. HAEMATOLOGICA
- A phase I dose-escalation study of the safety and pharmacokinetics of a tablet formulation of voxtalisib, a phosphoinositide 3-kinase inhibitor, in patients with solid tumors
- (2017) Janice M. Mehnert et al. INVESTIGATIONAL NEW DRUGS
- A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel
- (2017) Lillian M. Smyth et al. INVESTIGATIONAL NEW DRUGS
- Knockdown of long non-coding RNA MALAT1 inhibits growth and motility of human hepatoma cells via modulation of miR-195
- (2017) Dingli Liu et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Design, Synthesis, and Biological Evaluation of Dimorpholine Substituted Thienopyrimidines as Potential Class I PI3K/mTOR Dual Inhibitors
- (2017) Miao Zhan et al. JOURNAL OF MEDICINAL CHEMISTRY
- Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) José Baselga et al. LANCET ONCOLOGY
- Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial
- (2017) Andrew D Zelenetz et al. LANCET ONCOLOGY
- A Phase I Dose‐Escalation Study of the Safety and Pharmacokinetics of Pictilisib in Combination with Erlotinib in Patients with Advanced Solid Tumors
- (2017) Stephen Leong et al. ONCOLOGIST
- Phase I Dose‐Escalation Study of Pilaralisib (SAR245408, XL147) in Combination with Paclitaxel and Carboplatin in Patients with Solid Tumors
- (2017) Jennifer Wheler et al. ONCOLOGIST
- PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D
- (2017) Eneda Toska et al. SCIENCE
- Long noncoding RNA LINC01296 is associated with poor prognosis in prostate cancer and promotes cancer-cell proliferation and metastasis
- (2017) Jie Wu et al. OncoTargets and Therapy
- LncRNA OIP5-AS1 loss-induced microRNA-410 accumulation regulates cell proliferation and apoptosis by targeting KLF10 via activating PTEN/PI3K/AKT pathway in multiple myeloma
- (2017) Nan Yang et al. Cell Death & Disease
- Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors
- (2017) Dejan Juric et al. Cancer Discovery
- Long non-coding RNA HOTAIR acts as a competing endogenous RNA to promote malignant melanoma progression by sponging miR-152-3p
- (2017) Wenkang Luan et al. Oncotarget
- The dual PI3K/mTOR inhibitor dactolisib elicits anti-tumor activity in vitro and in vivo
- (2017) Fei Shi et al. Oncotarget
- Acquired resistance to PI3K/mTOR inhibition is associated with mitochondrial DNA mutation and glycolysis
- (2017) King Xin Koh et al. Oncotarget
- Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma
- (2017) Anas Younes et al. HAEMATOLOGICA
- Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials
- (2017) Sonali M Smith et al. Lancet Haematology
- 445ODOSE-ESCALATION STUDY OF SONIDEGIB (LDE225) PLUS BUPARLISIB (BKM120) IN PATIENTS (PTS) WITH ADVANCED SOLID TUMORS
- (2017) Q.S. Chu et al. ANNALS OF ONCOLOGY
- Ph IB study of LEE011 and BYL719 in combination with letrozole in ER+, HER2- breast cancer.
- (2017) Pamela N. Munster et al. JOURNAL OF CLINICAL ONCOLOGY
- Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias
- (2016) Brittany Knick Ragon et al. AMERICAN JOURNAL OF HEMATOLOGY
- First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas
- (2016) A. Patnaik et al. ANNALS OF ONCOLOGY
- A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2− advanced breast cancer (BELLE-4)
- (2016) M. Martín et al. ANNALS OF ONCOLOGY
- Phase II study of single agent buparlisib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL)
- (2016) C. Grommes et al. ANNALS OF ONCOLOGY
- PIK-ORL: A phase II, multicenter trial aiming to evaluate BKM120 in monotherapy in patients (pts) with metastatic/recurrent head and neck squamous cell carcinoma (HNSCC) after failure of platin and cetuximab or anti-EGFR-based therapy
- (2016) J. Fayette et al. ANNALS OF ONCOLOGY
- Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, placebo-controlled, phase II randomised PEGGY study
- (2016) P. Vuylsteke et al. ANNALS OF ONCOLOGY
- Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity
- (2016) B. L. Lampson et al. BLOOD
- Prognostic value of a newly identified MALAT1 alternatively spliced transcript in breast cancer
- (2016) Didier Meseure et al. BRITISH JOURNAL OF CANCER
- Phase Ib trial of the PI3K/mTOR inhibitor voxtalisib (SAR245409) in combination with chemoimmunotherapy in patients with relapsed or refractory B-cell malignancies
- (2016) Farrukh T. Awan et al. BRITISH JOURNAL OF HAEMATOLOGY
- A multicenter, single-arm, open-label, phase 2 study of apitolisib (GDC-0980) for the treatment of recurrent or persistent endometrial carcinoma (MAGGIE study)
- (2016) Vicky Makker et al. CANCER
- PDK1-SGK1 Signaling Sustains AKT-Independent mTORC1 Activation and Confers Resistance to PI3Kα Inhibition
- (2016) Pau Castel et al. CANCER CELL
- A Phase I study of intravenous PI3K inhibitor copanlisib in Japanese patients with advanced or refractory solid tumors
- (2016) Toshihiko Doi et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER + /HER2 − Metastatic Breast Cancer
- (2016) Ingrid A. Mayer et al. CLINICAL CANCER RESEARCH
- Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors
- (2016) S. O. Dolly et al. CLINICAL CANCER RESEARCH
- The role of long noncoding RNA HOTAIR in the acquired multidrug resistance to imatinib in chronic myeloid leukemia cells
- (2016) Haiying Wang et al. Hematology
- PI3K inhibitor LY294002, as opposed to wortmannin, enhances AKT phosphorylation in gemcitabine-resistant pancreatic cancer cells
- (2016) Yufeng Wang et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Phase Ia/Ib study of the pan-class I PI3K inhibitor pictilisib (GDC-0941) administered as a single agent in Japanese patients with solid tumors and in combination in Japanese patients with non-squamous non-small cell lung cancer
- (2016) Noboru Yamamoto et al. INVESTIGATIONAL NEW DRUGS
- Phase II Randomized Preoperative Window-of-Opportunity Study of the PI3K Inhibitor Pictilisib Plus Anastrozole Compared With Anastrozole Alone in Patients With Estrogen Receptor–Positive Breast Cancer
- (2016) Peter Schmid et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma
- (2016) Thomas Powles et al. JOURNAL OF CLINICAL ONCOLOGY
- Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial
- (2016) Ian E Krop et al. LANCET ONCOLOGY
- Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3K and PI3K , Demonstrates Treatment Strategies for PIK3CA-Dependent Breast Cancers
- (2016) K. Hudson et al. MOLECULAR CANCER THERAPEUTICS
- MSK1-Mediated β-Catenin Phosphorylation Confers Resistance to PI3K/mTOR Inhibitors in Glioblastoma
- (2016) Shaofang Wu et al. MOLECULAR CANCER THERAPEUTICS
- PI3Kγ is a molecular switch that controls immune suppression
- (2016) Megan M. Kaneda et al. NATURE
- LncRNA HOTAIR promotes cisplatin resistance in gastric cancer by targeting miR-126 to activate the PI3K/AKT/MRP1 genes
- (2016) Jin Yan et al. TUMOR BIOLOGY
- Long non-coding RNA BC087858 induces non-T790M mutation acquired resistance to EGFR-TKIs by activating PI3K/AKT and MEK/ERK pathways and EMT in non-small-cell lung cancer
- (2016) Hui Pan et al. Oncotarget
- HULC long noncoding RNA silencing suppresses angiogenesis by regulating ESM-1 via the PI3K/Akt/mTOR signaling pathway in human gliomas
- (2016) Yu Zhu et al. Oncotarget
- Long non-coding RNA CRNDE promotes gallbladder carcinoma carcinogenesis and as a scaffold of DMBT1 and C-IAP1 complexes to activating PI3K-AKT pathway
- (2016) Sheng Shen et al. Oncotarget
- Association of HOTAIR expression with PI3K/Akt pathway activation in adenocarcinoma of esophagogastric junction
- (2016) Zhang Hui et al. Open Medicine
- PI3K signalling in inflammation
- (2015) P.T. Hawkins et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS
- Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma
- (2015) C. Y. Cheah et al. BLOOD
- Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor
- (2015) Kimberly Blackwell et al. BREAST CANCER RESEARCH AND TREATMENT
- AXL Mediates Resistance to PI3Kα Inhibition by Activating the EGFR/PKC/mTOR Axis in Head and Neck and Esophageal Squamous Cell Carcinomas
- (2015) Moshe Elkabets et al. CANCER CELL
- Measurement of PIP3 Levels Reveals an Unexpected Role for p110β in Early Adaptive Responses to p110α-Specific Inhibitors in Luminal Breast Cancer
- (2015) Carlotta Costa et al. CANCER CELL
- First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies
- (2015) P. Munster et al. CLINICAL CANCER RESEARCH
- Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma
- (2015) Q. Yang et al. CLINICAL CANCER RESEARCH
- First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer
- (2015) G. I. Shapiro et al. CLINICAL CANCER RESEARCH
- A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors
- (2015) Johanna C. Bendell et al. INVESTIGATIONAL NEW DRUGS
- Phase 2 study of the pan-isoform PI3 kinase inhibitor BKM120 in metastatic urothelial carcinoma patients.
- (2015) Gopa Iyer et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer
- (2015) Johan F. Vansteenkiste et al. Journal of Thoracic Oncology
- The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models
- (2015) P. Foster et al. MOLECULAR CANCER THERAPEUTICS
- Phase II study of PX-866 in recurrent glioblastoma
- (2015) M. W. Pitz et al. NEURO-ONCOLOGY
- Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma
- (2015) Patrick Y. Wen et al. NEURO-ONCOLOGY
- Oncogenic activation of the PI3-kinase p110β isoform via the tumor-derived PIK3CβD1067V kinase domain mutation
- (2015) E Pazarentzos et al. ONCOGENE
- Phase I Dose-Escalation Study of Pilaralisib (SAR245408, XL147), a Pan-Class I PI3K Inhibitor, in Combination With Erlotinib in Patients With Solid Tumors
- (2015) J.-C. Soria et al. ONCOLOGIST
- Targeting the PI3K/AKT/mTOR pathway in squamous cell carcinoma of the head and neck
- (2015) Daniel R. Simpson et al. ORAL ONCOLOGY
- Targeting PI3 kinase in cancer
- (2015) Todd M. Bauer et al. PHARMACOLOGY & THERAPEUTICS
- Reciprocal regulation of GAS5 lncRNA levels and mTOR inhibitor action in prostate cancer cells
- (2015) Kiren Yacqub-Usman et al. PROSTATE
- PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor–positive breast cancer
- (2015) Ana Bosch et al. Science Translational Medicine
- Inhibition of DNA methyltransferase as a novel therapeutic strategy to overcome acquired resistance to dual PI3K/mTOR inhibitors
- (2015) Xiao-jun Qian et al. Oncotarget
- Knockdown of long non-coding RNA HOTAIR inhibits malignant biological behaviors of human glioma cells via modulation of miR-326
- (2015) Jing Ke et al. Oncotarget
- PI3K/AKT signaling pathway and cancer: an updated review
- (2014) Miriam Martini et al. ANNALS OF MEDICINE
- Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110 , for relapsed/refractory chronic lymphocytic leukemia
- (2014) J. R. Brown et al. BLOOD
- Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase- , as therapy for previously treated indolent non-Hodgkin lymphoma
- (2014) I. W. Flinn et al. BLOOD
- A phase 1 study of the PI3K inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL)
- (2014) B. S. Kahl et al. BLOOD
- Phase I/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer
- (2014) Sara Tolaney et al. BREAST CANCER RESEARCH AND TREATMENT
- Regulation of apoptosis by long non-coding RNA GAS5 in breast cancer cells: implications for chemotherapy
- (2014) Mark R. Pickard et al. BREAST CANCER RESEARCH AND TREATMENT
- CDK 4/6 Inhibitors Sensitize PIK3CA Mutant Breast Cancer to PI3K Inhibitors
- (2014) Sadhna R. Vora et al. CANCER CELL
- FoxO Transcription Factors Promote AKT Ser473 Phosphorylation and Renal Tumor Growth in Response to Pharmacologic Inhibition of the PI3K–AKT Pathway
- (2014) Aifu Lin et al. CANCER RESEARCH
- Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors
- (2014) Yuichi Ando et al. CANCER SCIENCE
- Cancer-Associated PTEN Mutants Act in a Dominant-Negative Manner to Suppress PTEN Protein Function
- (2014) Antonella Papa et al. CELL
- Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245409 (XL765), a Novel, Orally Administered PI3K/mTOR Inhibitor in Patients with Advanced Solid Tumors
- (2014) K. P. Papadopoulos et al. CLINICAL CANCER RESEARCH
- First-in-Human Study of CH5132799, an Oral Class I PI3K Inhibitor, Studying Toxicity, Pharmacokinetics, and Pharmacodynamics, in Patients with Metastatic Cancer
- (2014) S. Blagden et al. CLINICAL CANCER RESEARCH
- First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan-Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors
- (2014) D. Sarker et al. CLINICAL CANCER RESEARCH
- A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors
- (2014) P. L. Bedard et al. CLINICAL CANCER RESEARCH
- Targeting Drug-Resistant Prostate Cancer with Dual PI3K/mTOR Inhibition
- (2014) K.D. Tang et al. CURRENT MEDICINAL CHEMISTRY
- Stand Up to Cancer Phase Ib Study of Pan-Phosphoinositide-3-Kinase Inhibitor Buparlisib With Letrozole in Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer
- (2014) Ingrid A. Mayer et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Safety and Pharmacokinetic Study of the PI3K/mTOR Inhibitor SAR245409 (XL765) in Combination with Erlotinib in Patients with Advanced Solid Tumors
- (2014) Pasi A. Jänne et al. Journal of Thoracic Oncology
- Characterization of the Novel and Specific PI3K Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials
- (2014) C. Fritsch et al. MOLECULAR CANCER THERAPEUTICS
- SGK3 Mediates INPP4B-Dependent PI3K Signaling in Breast Cancer
- (2014) Jessica A. Gasser et al. MOLECULAR CELL
- Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor
- (2014) Dejan Juric et al. NATURE
- PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
- (2014) Ajay K. Gopal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
- (2014) Richard R. Furman et al. NEW ENGLAND JOURNAL OF MEDICINE
- CRNDE, a long non-coding RNA responsive to insulin/IGF signaling, regulates genes involved in central metabolism
- (2013) Blake C. Ellis et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors
- (2013) G. I. Shapiro et al. CLINICAL CANCER RESEARCH
- PAK1 Mediates Resistance to PI3K Inhibition in Lymphomas
- (2013) K. Walsh et al. CLINICAL CANCER RESEARCH
- RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer
- (2013) Violeta Serra et al. JOURNAL OF CLINICAL INVESTIGATION
- Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics
- (2013) Akintunde Akinleye et al. Journal of Hematology & Oncology
- BAY 80-6946 Is a Highly Selective Intravenous PI3K Inhibitor with Potent p110α and p110δ Activities in Tumor Cell Lines and Xenograft Models
- (2013) Ningshu Liu et al. MOLECULAR CANCER THERAPEUTICS
- Characterization of a Tumor-Associated Activating Mutation of the p110β PI 3-Kinase
- (2013) Hashem A. Dbouk et al. PLoS One
- Genetic heterogeneity of diffuse large B-cell lymphoma
- (2013) Jenny Zhang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- mTORC1 Inhibition Is Required for Sensitivity to PI3K p110 Inhibitors in PIK3CA-Mutant Breast Cancer
- (2013) M. Elkabets et al. Science Translational Medicine
- JAK2/STAT5 Inhibition Circumvents Resistance to PI3K/mTOR Blockade: A Rationale for Cotargeting These Pathways in Metastatic Breast Cancer
- (2012) Adrian Britschgi et al. CANCER CELL
- Inhibition of PI3K/mTOR Leads to Adaptive Resistance in Matrix-Attached Cancer Cells
- (2012) Taru Muranen et al. CANCER CELL
- Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies
- (2012) D. Mahadevan et al. EUROPEAN JOURNAL OF CANCER
- An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice
- (2012) Kathryn M. Kinross et al. JOURNAL OF CLINICAL INVESTIGATION
- Conditional activation of Pik3ca H1047R in a knock-in mouse model promotes mammary tumorigenesis and emergence of mutations
- (2012) W Yuan et al. ONCOGENE
- G Protein-Coupled Receptor-Mediated Activation of p110 by G Is Required for Cellular Transformation and Invasiveness
- (2012) H. A. Dbouk et al. Science Signaling
- Discovery and biological activity of a novel class I PI3K inhibitor, CH5132799
- (2011) Jun Ohwada et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity
- (2011) Sarat Chandarlapaty et al. CANCER CELL
- Intermittent Administration of MEK Inhibitor GDC-0973 plus PI3K Inhibitor GDC-0941 Triggers Robust Apoptosis and Tumor Growth Inhibition
- (2011) K. P. Hoeflich et al. CANCER RESEARCH
- The Selective Class I PI3K Inhibitor CH5132799 Targets Human Cancers Harboring Oncogenic PIK3CA Mutations
- (2011) H. Tanaka et al. CLINICAL CANCER RESEARCH
- Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors
- (2011) Johanna C. Bendell et al. JOURNAL OF CLINICAL ONCOLOGY
- Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor
- (2011) S.-M. Maira et al. MOLECULAR CANCER THERAPEUTICS
- A Mechanism for Synergy with Combined mTOR and PI3 Kinase Inhibitors
- (2011) Shujie Yang et al. PLoS One
- PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis
- (2011) N. Ilic et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors
- (2011) A. Chakrabarty et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Phosphoproteomic Analysis Identifies Grb10 as an mTORC1 Substrate That Negatively Regulates Insulin Signaling
- (2011) Y. Yu et al. SCIENCE
- ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor identified using the JFCR39 drug discovery system
- (2010) De-xin Kong et al. ACTA PHARMACOLOGICA SINICA
- Phosphoinositide 3-kinase delta (PI3Kδ) in leukocyte signaling and function
- (2010) Wai-Ping Fung-Leung CELLULAR SIGNALLING
- Bis(morpholino-1,3,5-triazine) Derivatives: Potent Adenosine 5′-Triphosphate Competitive Phosphatidylinositol-3-kinase/Mammalian Target of Rapamycin Inhibitors: Discovery of Compound26(PKI-587), a Highly Efficacious Dual Inhibitor
- (2010) Aranapakam M. Venkatesan et al. JOURNAL OF MEDICINAL CHEMISTRY
- Structure of the Human mTOR Complex I and Its Implications for Rapamycin Inhibition
- (2010) Calvin K. Yip et al. MOLECULAR CELL
- The role of PI 3-kinase p110β in AKT signally, cell survival, and proliferation in human prostate cancer cells
- (2010) Karen M. Hill et al. PROSTATE
- The Emerging Role of the Phosphatidylinositol 3-Kinase/ Akt/Mammalian Target of Rapamycin Signaling Network in Cancer Stem Cell Biology
- (2010) Alberto M. Martelli et al. Cancers
- The pyridinylfuranopyrimidine inhibitor, PI-103, chemosensitizes glioblastoma cells for apoptosis by inhibiting DNA repair
- (2009) M -A Westhoff et al. ONCOGENE
- PTEN and the PI3-Kinase Pathway in Cancer
- (2008) Nader Chalhoub et al. Annual Review of Pathology-Mechanisms of Disease
- Dissecting isoform selectivity of PI3K inhibitors: the role of non-conserved residues in the catalytic pocket
- (2008) Mark Frazzetto et al. BIOCHEMICAL JOURNAL
- Phosphatidylinositol 3-kinase inhibitors: promising drug candidates for cancer therapy
- (2008) Dexin Kong et al. CANCER SCIENCE
- The Identification of 2-(1H-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer†
- (2008) Adrian J. Folkes et al. JOURNAL OF MEDICINAL CHEMISTRY
- Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis
- (2008) Christian Stockmann et al. NATURE
- Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
- (2008) Jeffrey A Engelman et al. NATURE MEDICINE
- Helical domain and kinase domain mutations in p110 of phosphatidylinositol 3-kinase induce gain of function by different mechanisms
- (2008) L. Zhao et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started